Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) have earned a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $11.00.

A number of analysts have issued reports on EVAX shares. Weiss Ratings upgraded shares of Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Evaxion A/S in a report on Friday, April 24th.

Evaxion A/S Stock Performance

Evaxion A/S stock opened at $2.82 on Monday. Evaxion A/S has a 1 year low of $2.45 and a 1 year high of $12.15. The firm’s 50 day moving average price is $3.35 and its 200-day moving average price is $3.67. The company has a debt-to-equity ratio of 0.41, a current ratio of 5.85 and a quick ratio of 5.85. The stock has a market cap of $23.52 million, a P/E ratio of -1.92 and a beta of 0.29.

Evaxion A/S (NASDAQ:EVAX) last issued its earnings results on Thursday, May 7th. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.43). On average, equities analysts predict that Evaxion A/S will post -0.5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Evaxion A/S

A number of hedge funds have recently made changes to their positions in EVAX. Wesbanco Bank Inc. bought a new position in Evaxion A/S during the fourth quarter valued at approximately $48,000. Northwestern Mutual Wealth Management Co. bought a new stake in Evaxion A/S in the 4th quarter worth approximately $38,000. SmartHarvest Portfolios LLC bought a new stake in Evaxion A/S in the 4th quarter worth approximately $72,000. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in shares of Evaxion A/S during the 1st quarter worth approximately $112,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of Evaxion A/S during the 1st quarter worth approximately $146,000. 11.04% of the stock is currently owned by hedge funds and other institutional investors.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.